[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342132-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342132-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","trim47-is-a-prognostic-biomarker-for-gallbladder-cancer-and-promotes-tumor-progression-through-regulating-k63-linked-ubiquitination-of-parp1","TRIM47 is a prognostic biomarker for gallbladder cancer and promotes tumor progression through regulating K63-linked ubiquitination of PARP1","","Gallbladder cancer (GBC) is a highly lethal malignancy with poor outcomes, and effective prognostic biomarkers and therapeutic targets remain limited. This study evaluates TRIM47 in GBC, assessing its clinical significance and biological function using immunohistochemistry, in vitro and in vivo functional assays, and mechanistic experiments including mass spectrometry, western blotting, and immunoprecipitation. TRIM47 is upregulated, correlates with shorter overall survival, and promotes GBC proliferation and migration while influencing apoptosis via PARP1-mediated K63-linked ubiquitination and AKT pathway activation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/trim47-is-a-prognostic-biomarker-for-gallbladder-cancer-and-promotes-tumor-progression-through-regulating-k63-linked-ubiquitination-of-parp1/342132/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/trim47-is-a-prognostic-biomarker-for-gallbladder-cancer-and-promotes-tumor-progression-through-regulating-k63-linked-ubiquitination-of-parp1/342132.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does TRIM47 play in gallbladder cancer prognosis?","Question",{"text":63,"@type":64},"TRIM47 is upregulated in GBC tissues and is associated with shorter overall survival, indicating prognostic value.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does TRIM47 promote tumor progression in GBC?",{"text":68,"@type":64},"TRIM47 promotes GBC cell proliferation and migration and affects apoptosis by interacting with PARP1 and mediating K63-linked polyubiquitination that stabilizes PARP1.",{"name":70,"@type":61,"acceptedAnswer":71},"Which signaling pathway is activated by TRIM47 through PARP1?",{"text":72,"@type":64},"TRIM47 activates the AKT signaling pathway via PARP1.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342132,1790196262,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Translational Oncology 51 (2025) 102164  \nContents lists available at ScienceDirect Translational Oncology  \njournal [homepage:](homepage: www.elsevier.com/locate/tranon)[ www.elsevier.com/locate/tranon](homepage: www.elsevier.com/locate/tranon)  \n| TRIM47 is a prognostic biomarker for gallbladder cancer and promotes tumor progression through regulating K63-linked ubiquitination of PARP1 Ming Xu a, Chuanmin Denga, Zhongran Mana, Hongyi Zhu a,b,*\u003Cbr>a Department of Hepatic-Biliary-Pancreatic Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China b Department ofBiliary-Pancreatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords: Gallbladder cancer Prognosis TRIM47\u003Cbr>PARP1\u003Cbr>Ubiquitination |  | Background: Gallbladder cancer (GBC) is one of the most lethal malignancies worldwide with an extremely poor prognosis. Previous studies have suggested that tripartite motif containing 47 (TRIM47) is involved in the progression of numerous cancers. However, the molecular mechanism and function of TRIM47 in GBC remain unclear.\u003Cbr>Methods: The clinical significance of TRIM47 was evaluated using immunohistochemistry. Functional assays were performed in vitro and in vivo to determine the role of TRIM47 in GBC. Mass spectrometric analysis, western blotting, and immunoprecipitation assays were performed to investigate the molecular mechanisms involved. Results: In this study, TRIM47 was upregulated in GBC tissues and associated with shorter overall survival ratesand TRIM47 was involved in GBC cell proliferation, migration, and apoptosis. Mechanistically, TRIM47 interacts with PARP1 and mediates the K63-linked polyubiquitination of PARP1, thereby stabilizing its expression. Furthermore, TRIM47 activated the AKT signaling pathway via PARP1.\u003Cbr>Conclusion: The present study revealed that TRIM47 contributes to the progression of GBC and is therefore an important biomarker for predicting the prognosis of GBC and for therapeutic intervention. |\n\nIntroduction  \nGallbladder cancer (GBC) is the most prevalent malignancy of the biliary tract and ranks sixth among gastrointestinal tract cancers [1–3]. The incidence of GBC has steadily increased in several countries, especially Southeast Asia, over the past few years [4,5]. The most effective treatment option for GBC is surgical excision of the primary tumor and locoregional dissemination. Regrettably, GBC patients are often diagnosed at an advanced stage and are ineligible for curative resection because of the absence of characteristic early symptoms and tumor markers [6,7]. Although systemic chemotherapy can prolong overall survival, the median survival duration is only 6–12 months [8]. Screening, detection, and early diagnosis are crucial for clinicians to devise targeted therapies, which is essential for improving the survival rates of GBC. Therefore, a comprehensive understanding of the molecular mechanisms governing the progression of GBC by identifying specific tumor markers is crucial for the discovery of new diagnostic and therapeutic approaches.  \nUbiquitination is a posttranslational modification of proteins that plays a significant role in degrading proteins and regulating most  \ncellular functions. Tripartite motif (TRIM) proteins belong to the RING family of ubiquitin E3 ligases, which have three conserved domains: RING, B-Box, and coiled-coil (RBCC). Many physiological processes are regulated by TRIM family proteins, including autophagy, innate immunity, cell proliferation and carcinogenesis [9–11]. TRIM47, a member of the TRIM family proteins, plays a critical role in several biological processes and in tumorigenesis. It is mainly located in the nucleus and is thought to be closely associated with nuclear receptor binding [12]. According to previous studies, TRIM47 is a novel biomarker for the progression of various cancers, suc","cbCaigQ29Nvr4yhb","https://ap.wps.com/l/cbCaigQ29Nvr4yhb","pdf",14744806,"English","# Abstract\n# Introduction\n# Materials and methods\n## Patient samples","[{\"question\":\"What role does TRIM47 play in gallbladder cancer prognosis?\",\"answer\":\"TRIM47 is upregulated in GBC tissues and is associated with shorter overall survival, indicating prognostic value.\"},{\"question\":\"How does TRIM47 promote tumor progression in GBC?\",\"answer\":\"TRIM47 promotes GBC cell proliferation and migration and affects apoptosis by interacting with PARP1 and mediating K63-linked polyubiquitination that stabilizes PARP1.\"},{\"question\":\"Which signaling pathway is activated by TRIM47 through PARP1?\",\"answer\":\"TRIM47 activates the AKT signaling pathway via PARP1.\"}]","TRIM47 is a prognostic biomarker for gallbladder cancer and promotes tumor progression through regulating K63-linked ubiquitination of PARP1 | PDF",1790045413,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ecd0b5f2dc5c461a88d21106b9a95640.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb6e0f9618383c5a9d8901be07626fe0.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09312f04bb1a89e39a6a83c60023eac7.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1fa2aaa8cad60b95c31867747196c21f.webp",980,1306]